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Magnocellular Vasopressin and the
Mechanism of “Glucocorticoid
Escape”
Ferenc A. Antoni*
Centre for Discovery Brain Sciences, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, United Kingdom
It is now widely accepted that magnocellular vasopressinergic neurons in the supraoptic
and paraventricular nuclei participate in the control of adrenocorticotropin secretion by
the anterior pituitary gland. However, it remains to be explored in further detail, when and
how these multifunctional neurons are involved in the control of anterior pituitary function.
This paper highlights the role of magnocellular vasopressin in the hypothalamic pituitary
adrenocortical axis with special reference to escape from glucocorticoid feedback
inhibition. The signaling mechanisms underlying glucocorticoid escape by pituitary
corticotrope cells, as well as the wider physiologic and pathologic contexts in which
escape is known to occur—namely strenuous exercise, and autoimmune inflammation
will be considered. It is proposed that by inducing escape from glucocorticoid feedback
inhibition at the pituitary level, magnocellular vasopressin is critically important for the
anti-inflammatory, and immunosuppressant actions of endogenous corticosteroids.
Keywords: vasopressin, adrenal corticosteroids, ACTH, dexamethasone non-suppression, interleukin-6, agonist-
induced plasticity
INTRODUCTION
This paper is the consequence of a symposium held in the honor of the late Dr. Kevin J. Catt
(1932–2017) at Semmelweis University in Budapest. As a first year student at this institution, which
has a tradition of teaching medicine for 250 years, I was handed the course textbook, “Functional
Anatomy” by János Szentágothai (Schimmer) (1). First published as a single author book in 1971,
this tome managed a readable, if in places decidedly subjective synthesis of classic gross anatomy
and histology with modern studies of ultrastructure, physiology, and biochemistry. The didactic
approach was unashamedly teleologic in emphasizing the unity of form and function. However, it
went beyond Aristotelian metaphysics. It was an almost poetic celebration of the harmony of the
human body, of how, from single cells to complex organs, structure reflected purpose, and function.
The scientific oeuvre of Kevin Catt heralds the beginning of a new era where the structures and
regulatory properties of cells are pared back to their ultimate molecular constituents. Now in full-
swing, this era of discovery is best symbolized by the complex analysis of individual cells, involving
the combination of multi-parameter imaging with transcriptomics, and proteomics (2).We are able
to map how the seemingly stochastic expression of genes underpins the functional plasticity of cell
populations to support macroscopic physiologic reflexes and control mechanisms. This review aims
to follow the path of Szentágothai in the quest for achieving the synthesis of structure and function,
also incorporating the molecular insights of cellular signaling pathways pioneered by Kevin Catt.
Antoni Glucocorticoid Escape and Vasopressin
AN OUTLINE OF THE HYPOTHALAMIC-
PITUITARY-ADRENOCORTICAL AXIS
The hypothalamic-pituitary-adrenocortical system comprises
a classic neuroendocrine regulatory feedback circuit.
Neuroendocrine neurons in the hypothalamus drive the secretion
of adrenocorticotropin (ACTH) by releasing neuropeptides,
namely 41-residue corticotropin releasing-factor (CRF) and
vasopressin (VP), into hypophysial portal blood-vessels that
irrigate the anterior pituitary gland (3). These neurons receive
a large number of diverse neural inputs from various parts of
the brain that contribute to the hormonal response to stress
(4–8). The production and secretion of steroid hormones—
glucocorticoids, as well as mineralocorticoids—by the adrenal
cortex is stimulated by ACTH secreted by the pituitary gland.
An important effect of the steroids is to provide inhibitory
feedback at the level of hypothalamic neroendocrine neurons,
adenohypophysial corticotropes, as well as the higher brain
centers involved in the control of neuroendocrine neurons
(9, 10). The relative importance of the site(s) of feedback
inhibition that govern the size and duration of the HPA response
to stress may be dependent on the biological paradigm analyzed.
In clinical practice, HPA responsiveness is usually assessed by
some form of the dexamethasone suppression-test (11), utilizing
a synthetic steroid largely selective for Type II glucocorticoid
receptors (10). The main site of feedback tested by this paradigm
appears to be the anterior pituitary corticotrope cell (12, 13).
VASOPRESSIN
Vasopressin (VP) is a small, COOH-terminally amidated peptide
chiefly synthesized by nerve cells, hence designated as a
neuropeptide. Arginine-vasopressin is the most common form in
mammals, but in some species Arg is replaced by Lys see review
by Bichet (14). Vasopressin is elaborated upon the processing
of a larger protein precursor—preprovasopressin (15), which is
packaged and processed in dense-core secretory granules that
are transported to sites of release along the axon as well as
the dendrites (15, 16). Note that neurophysin II and copeptin,
the COOH-terminal segment of the precursor, are also co-
secreted with VP. The biological role of copeptin is unknown.
However, its stability in human plasma and immunogenicity
has been exploited to use copeptin as surrogate for the activity
of VP-secreting neurons with intriguing results (17, 18). The
cellular actions of VP are mediated by G protein-coupled 7-
transmembrane domain receptors. Of these, the V1b isoform
appears most relevant for the stress response (19, 20).
FUNCTIONAL NEUROANATOMY OF
VASOPRESSINERGIC NEURONS OF THE
HYPOTHALAMUS
The Magnocellular System
The magnocellular neurosecretory system of the hypothalamus
was discovered a relatively long time ago, on the basis of the
distinct histochemical reaction produced by the high amounts
of neurohormone elaborated by these neurons reviewed by
Scharrer (21). The cell bodies are found in the supraoptic and
paraventricular hypothalamic nuclei and send their axons to
terminate in the neurohemal interface zone located at the bottom
of the hypothalamus. The neurohemal interface is comprised
of the median eminence and the posterior lobe of the pituitary
gland also referred to as the neurohypophysis. Magnocellular
neurons constitute the classic antidiuretic system that is activated
by hypernatremia or hypovolemia and releases VP into the
systemic circulation (14). Subsequent work has shown that the
axons of magnocellular neurons also release VP en-passant in
the internal zone of the median eminence (22–24). The VP
released by this process appears in pituitary portal blood that
irrigates the anterior pituitary gland [(25), also see Box 1]. It is
of note, that magnocellular VP neurons also release vasopressin
from their dendrites (16). Whether or not dendritic release
contributes to the control of the pituitary secretion of ACTH
remains to be clarified. However, it is well-established that
magnocellular neurons make various forms of contact with
CRF producing cells in the medial parvicellular paraventricular
nucleus of the hypothalamus (26, 27). Moreover, Plotsky and co-
workers found that in rats VP given into the 3rd cerebral ventricle
attenuated the release of CRF into hypophysial portal blood
and, conversely, inhibition of AVP action increased the levels of
CRF (28). These results indicate that there may be a functional
link between the magnocellular VP neurons and parvicellular
neurons producing CRF.
Parvicellular Neurons Producing CRF
and VP
A second population of VP-ergic neurons projecting to the
median eminence is located in the medial parvicellular part
of the hypothalamic paraventricular nucleus. These are small
neurons that also co-produce and co-package CRF with VP
(29, 30) and are the key neuroendocrine neurons that regulate
the pituitary secretion of ACTH (31, 32). With respect to
the stress response two functional differences between the
magnocellular and parvicellular neurons are of note. First, under
Box 1 | Six decades of dogma-busting: The magnocellular
vasopressinergic neuron as a modulator of anterior pituitary ACTH
secretion.
1. Neurosecretion into the bloodstream-non-conforming to neuron
doctrine.
2. Negates single hypothalamic releasing hormone for each pituitary
hormone hypothesis.
3. VP is not just the antidiuretic hormone (ADH).
4. Secretory path from internal zone of the median eminence into pituitary
portal blood-“en passant” neuropeptide release.
5. Negates the hyophyseotrophic area = the mediobasal hypothalamus
concept.
6. VP alone has no ACTH releasing effect at physiologic concentrations i.e.,
it is a new type of neuroendocrine modulator, a major action of which is
to induce glucocorticoid resistance at the level of the corticotrope cell.
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normal conditions, magnocellular neurons produce up to 10-
fold more VP than parvicellular neurons (30, 33). Second,
the production and release of VP by parvicellular neurons is
under prominent inhibitory control by adrenal corticosteroids
(34), while that in magnocellular neurons is not (35).This is
despite the fact that magnocellular VP neurons express Type
II glucocorticoid receptors (36). In the absence of adrenal
corticosteroids, VP release from the parvicellular neurons is
massively increased and becomes comparable to that from
magnocellular neurons (33, 37).
The Relevance of Magno- and
Parvi-Cellular VP-Ergic Neurons to the
Stress Response
The role of VP and its pituitary V1b receptor in the stress
response has been analyzed in considerable detail in various
models, including genetically vasopressin-deficient Brattleboro
rats (38) and V1b receptor gene-deleted mice (20). These
studies, and many others see (39) for review, support an
important role for VP in the stimulatory control of stress-induced
ACTH secretion. However, very few studies have attempted to
distinguish between the effects of parvicellular andmagnocellular
VP. Plotsky and Thivikraman first produced evidence showing
that glucocorticoid negative feedback appeared to be absent in
conscious rats subjected to repeated moderate hemorrhage (40).
Subsequently, these workers showed that HPA activation by air-
puff startle, a psychological stressor, was sensitive to inhibition
by corticosterone whereas that caused by small or moderate
hemorrhage was not (41). Moreover, they found early immediate
gene activation in magnocellular neurons of the supraoptic and
paraventricular hypothalamic nuclei during hemorrhage and
activation in the dorsomedial part of the hypothalamus by air-
puff startle. Thus, this work differentiated feedback prone and
feedback resistant mild stressors and observed signs of activation
in magnocellular hypothalamic neurons in the case of the latter.
SIGNAL INTEGRATION BY
CORTICOTROPE CELLS OF THE
ANTERIOR PITUITARY GLAND AND THE
VP-INDUCED ESCAPE FROM INHIBITION
BY GLUCOCORTICOIDS
The stimulatory input to corticotrope cells is comprised
of CRF and VP. A hypothalamic ACTH-inhibiting factor,
atrial natriuretic peptide (ANP) has also been identified
(39, 42). Finally, corticotrope cells are a well-established site of
glucocorticoid feedback-inhibition (9, 10).
CRF
The widely accepted mechanism of action in the case of CRF
is activation of CRF1 receptors and conservative coupling
to the stimulatory G protein Gs. The consequent activation
of transmembrane adenylyl cyclase(s) leads to increase of
intracellular cAMP levels (43). The scenario of intracellular
signaling downstream of cAMP is complex, as reviewed in detail
elsewhere (44, 45). However, it is clear that intracellular Ca2+
signals are generated by CRF, and that the electrical activity of
the cells ultimately determines the secretion of ACTH.
VP
In the case of VP, the consensus is the activation of V1b receptors
coupled to Gq and consequent activation of PLC, with ensuing
increases of IP3 levels and PKC activity. Exactly which isoform(s)
of PKC is (are) involved, is not entirely clear, but as phorbol
esters can mimic most of the known actions of VP including
the potentiation of the cAMP signal and the stimulation of
ACTH secretion, the alpha and beta PKC-isoforms are the likely
candidates. Once more, events after IP3 and PKC activation are
too complex to be considered here (44, 46).
ANP
There is a signaling pathway to inhibit stimulated ACTH
secretion through 3′5′guanosine monophosphate (cGMP), that
is not shared with glucocorticoids (47). This pathway can be
activated by ANP (48, 49), and may become functionally more
prominent under conditions where the pituitary corticotropes
are in “glucocorticoid escape” mode.
Glucocorticoids
Feedback inhibition in the HPA axis occurs in three time-
domains; rapid<15min, early delayed—within 20min and up to
2 h, and delayed, beyond 2 h (9, 10, 50). With respect to the time-
domains of feedback manifested in corticotropes: in contrast to
a recent study (51), we have failed to observe a rapid inhibitory
effect of glucocorticoids in dispersed rat anterior pituitary (52)
or AtT-20D16:16 mouse corticotrope tumor cells (53). Thus, the
focus of the studies outlined here was early-delayed feedback,
which is the main inhibitory effect in the first 2 h after exposure
to glucocorticoids. The properties of this inhibition have been
reviewed extensively (9, 54, 55). In brief, it is mediated by
Type II glucocorticoid receptors and is sensitive to inhibitors
of transcription and translation, indicating a requirement of
mRNA synthesis/processing and protein synthesis (52). What is
the molecular and cellular basis of early- delayed inhibition? In
AtT-20 cells, the balance of cAMP-dependent phosphorylation
on the stress-axis-regulated-insert (STREX) type α-subunit of the
large conductance Ca2+-dependent K+-channel (BK-channel)
is shifted toward dephosphorylation. As a result, the channel
is not inhibited by cAMP-dependent phosphorylation induced
by CRF (56). Hence, the enhancement of intracellular free
Ca2+ transients and the consequent stimulation of ACTH
secretion by CRF are suppressed, reviewed in refs (54, 57).
Subsequent work has implicated a protein phosphatase 2A-
like enzyme as the mediator of glucocorticoid action (58), but
definitive evidence is still outstanding. In contrast to AtT20 cells,
blockade of BK-channels had no appreciable effect on the efficacy
of corticosterone to inhibit CRF-induced ACTH secretion in
cultured rat anterior pituitary cells (59). This is despite the
fact, that BK channels play a prominent role in governing the
firing pattern and the intracellular Ca2+ transients of anterior
pituitary cells in culture (57) and that corticosterone has an
inhibitory effect on the bursting activity of mouse corticotropes
cells (44). Moreover, inhibition of agonist-induced ACTH release
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FIGURE 1 | Agonist-induced plasticity of cAMP signaling—multiple functional states of the adenohypophysial corticotroph cell. AC, adenylyl cyclase; CaM,
calmodulin; EPAC, exchange factors directly activated by cAMP; HCN, Hyperpolarization activated cyclic nucleotide gated channels; PDE- cyclic nucleotide
phosphodiesterase; PKA, cAMP dependent protein kinase; PKC, protein kinase C; PLC, phospholipase C; PPase2B, protein phosphatase 2B (alias calcineurin).
Arrows indicate facilitation, T-bars indicate inhibition. The size and thickness of the lettering is proportional to the amplitude/activity of the denoted entity.
by ANP/cGMP, could be reversed by blockers of BK as well
as other K+ channels (60). In contrast, studies with a variety
of K+ inhibitors failed to identify conclusively the K+ channel
key for early delayed inhibition by corticosteroids (61). Others,
using a similar panel of K+ channel blockers, reported a role
for ether-á-go-go-related gene K+-channels as the mediators of
glucocorticoid inhibition (62). However, these findings have not
been confirmed by other, more direct methods, such as patch-
clamp electrophysiology or gene-knock down. In summary,
current evidence indicates that early-delayed corticosteroid
feedback inhibition at the pituitary level is by glucocorticoid-
induced protein(s) that facilitate the activation of K+-channels.
A similar conclusion was reached in a study of hippocampal
pyramidal neurons (63). Significantly, this scenario implies that
glucocorticoid inhibition is sensitive to depolarization of the
membrane potential (59, 64).
One of the complicating factors in understanding signaling
processes in corticotropes is the variety of the in vitro models
used. It is clear that cultured cells, acutely dispersed cells, and
pituitary slices may have different properties. Moreover, the
temporal dynamics in perifused tissue are different to that seen
in static systems. Finally, the concentrations of the effectors
employed tend to vary from physiologic (CRF up to 0.3 nM, VP
up to 3 nM) to the grossly aphysiologic.
With these considerations in mind, a detailed analysis of
CRF-induced cAMP levels was carried out in the context of the
inhibition of cAMP synthesis by intracellular free Ca2+, and the
efficacy of corticosteroid feedback inhibition of stimulated ACTH
release. It transpired that CRF-induced cAMP synthesis is under
feedback inhibition by Ca2+ derived from a ryanodine/caffeine
sensitive intracellular pool (65). However, above 1 nM CRF, the
effect of Ca2+ was no longer apparent. A similar “escape” of CRF-
induced cAMP synthesis from Ca2+ inhibition could be induced
by physiologic concentrations of VP, an effect also mimicked
by phorbol-ester activation of protein kinase C (65). Analysis
of cAMP hydrolysis indicated that while PDE4 isoforms were
active when low concentrations of CRF were used, inhibitors of
PDE1 were required for inhibiting cAMP breakdown when CRF
was applied in combination with VP. When interpreted in the
context of the diversity of cAMP signaling proteins (66, 67), the
results indicate that physiologic concentrations of CRF activate a
Ca2+ inhibited adenylyl cyclase such as AC5, 6, or 9, while in the
presence of VP an adenylyl cyclase activated by protein kinase C
such as AC2 or AC7 enters the fray (Figure 1). This latter cyclase
is responsible for the markedly increased cAMP levels that
require high-capacity, low-affinity phosphodiesterases to control
cAMP signaling. By the combination of immunocytochemistry,
Western blotting and RT-PCR, we concluded that AC7, PDE1a,
and PDE1b were the best candidates underlying the switching
of corticotropes to high cAMP levels in the context of
stimulation by CRF and VP. Importantly, VP was present at
concentrations that are only produced by magnocellular neurons
under physiologic conditions.
It is pertinent to highlight here that the “amplitude
modulation” of the cAMP signal outlined above has potentially
important consequences: whilst PKA is maximally active at
1µM cAMP, other effectors such as EPACS, hyperpolarization-
activated cyclic nucleotide–gated (HCN) channels, and cyclic
nucleotide gated channels all require >10µM cAMP for
activity. Thus, a whole plethora of cAMP signaling systems is
potentially mobilized in corticotrope cells in the presence of high
(magnocellular) concentrations of VP that are not active at levels
of stimulation that can be achieved via parvicellular CRF/VP. It
is also important to reiterate here that the effects of VP on cAMP
synthesis are conditional to the presence of CRF.
Several of the inferences in the aforementioned studies
were made on the basis of the application of pharmacologic
agents or the use of antibodies. It later transpired, that the
antibodies used to localize AC2 in the anterior pituitary gland
were unreliable, similarly, an antibody against AC5/6 gave also
inconsistent results (68). More recently, mRNA-seq analyses of
single anterior pituitary cells have been published (69). The
data show selective enrichment of AC2 in corticotrope cells, in
contrast, the levels of AC7 mRNA in anterior pituitary cells are
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FIGURE 2 | Glucocorticoid escape at the pituitary gland induced by
magnocellular VP to mobilize the endogenous immunosuppressant activity of
adrenal corticosteroids. pPVN, parvicellular medial dorsal part of the
hypothalamic paraventricular nucleus; mPVN lateral magnocellular part of the
PVN; SON, supraoptic hypothalamic nucleus.
very low. All three Ca2+-inhibited ACs, AC5, 6, and 9 appear
to be expressed in corticotropes. Moreover, the highest relative
levels of PDE1a and PDE1b appear to be associated with cells
identified as corticotropes.
Taken together, the molecular machinery of Ca2+ feedback
on cAMP biosynthesis and for achieving the VP-mediated
boost of cellular cAMP to levels that address EPACS, HCNs
and CNGs is present in corticotropes. Finally, is attractive to
speculate here, that high VP overrides early feedback through
depolarization of the membrane potential by activation of an
HCN channel (70, 71).
The analysis of the efficacy of corticosterone to inhibit
CRF-induced ACTH release showed interesting parallels with
the characteristics of the inhibition of cAMP synthesis by
Ca2+(61). In the physiologic range for CRF, corticosterone
inhibition was highly efficient, while at supraphysiological CRF
the inhibitory efficacy was markedly reduced. Application of
the PDE4 blocker rolipram or high, physiologic levels of
VP with physiologic concentrations of CRF also markedly
reduced the inhibitory efficacy of corticosterone. In essence,
irrespective of how intracellular cAMP levels were elevated
above 20µM, glucocorticoid efficacy was progressively reduced.
Thus, if the agonists by-pass the Ca2+ inhibitory feedback
on adenylyl cyclase, the efficacy of glucocorticoid inhibition is
dramatically reduced. These observations link the VP mediated
switch of low cAMP signaling induced by CRF to high cAMP,
with the escape from glucocorticoid feedback at the pituitary
level. A summary cartoon of the corticosteroid sensitive and
insensitive states of anterior pituitary corticotrope cells is shown
in Figure 1.
WHEN IS GLUCOCORTICOID ESCAPE OF
BIOLOGICAL IMPORTANCE?
The pronounced deleterious effects of long-term corticosteroid
excess on body homeostasis indicate that glucocorticoid escape
is encountered in life-threatening situations and is likely to be
of relatively short duration. The classic clinical examples of
persistent glucocorticoid non-suppression are Cushing’s disease
(72) and melancholic depression (12).
Autoimmune Inflammation
In preclinical models of autoimmune inflammation, such as
experimental autoimmune encephalomyelitis and adjuvant-
induced arthritis, a sustained rise of plasma corticosteroids
lasting several days is crucial for survival (73). Indeed, it is
widely recognized that adrenal corticosteroids are important
facilitators of endogenous immunosuppression (74). The only
way this can occur is by escape from glucocorticoid feedback
inhibition. Several lines of evidence indicate, that the sustained
and vital increase of corticosteroids in preclinical autoimmune
models is mediated by VP (75, 76). Moreover, the data of Suzuki
etal. (76), indicated at the level of VP expression rather than
mRNA, that magnocellular vasopressinergic neurons become
activated during autoimmune inflammation. It is relevant to
recall here that VP synthesis is not closely controlled by adrenal
corticosteroids in magnocellular neurons (35) and that the effects
of low levels of CRF on corticotropes are amplified dramatically
by VP (65, 77). Thus, activation of magnocellular VP neurons
can bypass glucocorticoid feedback in the CNS and induce
escape from glucocorticoid feedback at the pituitary level to
support the sustained secretion of corticosteroids. The trigger
for the activation of hypothalamic neurons during autoimmune
inflammation is unknown. It is plausibly a cytokine, above all,
interleukin-6 (IL-6) (78) known to activate the HPA axis in
humans as well as rodents (79). However, the exact mechanism
by which this occurs remains to be clarified (80). Intriguingly,
magnocellular VP neurons also produce IL-6 (81). Moreover,
increases of IL-6 levels in magnocellular neurons were observed
after various types of stress paradigms (82). Whether or not this
IL-6 is involved in the regulation VP release e.g., as a paracrine
mediator, is unknown. A summary diagram of the by-pass of
glucocorticoid feedback in the HPA axis through the activation
of magnocellular VP neurons by immune mediators is shown
in Figure 2.
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High Intensity Exercise and Hyponatremia
Work by Deuster et al. (83) reported that high-intensity exercise
results in dexamethasone non-suppression in men as well
as women. One of the threats of high-intensity exercise is
hyponatremia (84), which may be lethal due to the development
of hypotonic encephalopathy (85). Increases of plasma VP are
prominent under these conditions and it has been argued that
exercise-associated hypernatremia is a case of inappropriate VP
secretion (SIADH). It is likely, that IL-6 released from muscle
cells during exercise is a trigger for VP secretion. Additionally,
hyperhydration by the subjects during exercise may contribute
to hyponatremia. In the pituitary portal system, where VP levels
are considerably higher than in the periphery, the levels of
vasopressin are sufficient to induce glucocorticoid escape at
the pituitary level. The ensuing higher levels of ACTH would
enhance aldosterone secretion by zona glomerulosa cells and
improve sodium retention. In addition, VP has a direct action to
stimulate aldosterone secretion in rat (86) as well as human zona
glomerulosa cells (87). Thus, while exercise may symptomatically
mimic SIADH in that plasma levels of VP increase despite
hypoosmolarity, it may be a fluid-volume preservation reflex that
simultaneously promotes sodium retention by bringing about
glucocorticoid non-suppression at the pituitary level.
SUMMARY
In a day-to-day setting, the activity of the HPA axis is under
powerful feedback inhibitory control. The situation during
certain types of stress may be different. In a seminal review,
Munck et al. (88) proposed that the physiologic rationale
of stress-induced glucocorticoid production was to dampen
and reset the production of powerful immune mediators
induced by the stress response. Three decades, two dozen
cytokines and a few microbiomes later, this concept is
stronger than ever. In particular, the emergence of IL-6
as a pleiotropic stress-responsive protein and its activation
of the hypothalamic CRF and VP systems is of particular
note. If corticosteroids are controlled by strict neuroendocrine
feedback tailored for stress-free and/or casual mild stress
conditions, they could not be deployed to combat stress with
a substantial inflammatory component. Increasingly, it appears
that most types of stress also mobilize inflammatory mediators
(89, 90). Similarly, given the threat of hyponatremia in severe
hypovolemia, overriding inhibitory feedback to allow sodium
retention through aldosterone may be key to survival. Therefore,
feedback inhibition has to be plastic. Indeed, the functional
neuroanatomy, as well as the molecular and cellular elements
underpinning the plasticity of corticosteroid feedback inhibition
are clearly apparent in the hypothalamo-hypophysial system.
Where sustained secretion of adrenal corticosteroids is vital for
survival, the evidence points to a critical role of magnocellular
VP to induce glucocorticoid escape at the pituitary level.Whether
or not this insight can be exploited therapeutically remains to
be explored.
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